UHN's Breakthrough Hepatitis B Liver Atlas: First Single-Cell Map of Liver and Immune Cells in Chronic Model

The Dawn of a New Era in HBV Research

University Health Network (UHN) scientists in Toronto have achieved a milestone in liver disease research by unveiling the first comprehensive single-cell atlas of liver and immune cells in a preclinical model of chronic Hepatitis B virus (HBV) infection. This breakthrough, detailed in the Journal of Hepatology, maps over 52,000 healthy liver cells and 40,000 from chronically infected livers, alongside peripheral blood mononuclear cells (PBMCs), using advanced single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics. 52 50 Led by Dr. Sonya MacParland, a Tier 2 Canada Research Chair in Liver Immunobiology at UHN and Professor at the University of Toronto, the atlas reveals intricate cellular changes that mirror human HBV pathology, offering unprecedented insights into disease progression and potential therapies.

Chronic HBV affects approximately 254 million people globally, with 1.2 million new infections annually, and remains a leading cause of hepatocellular carcinoma (HCC), the most common liver cancer. 64 In Canada, prevalence hovers around 0.48%, equating to roughly 190,000 cases, disproportionately impacting immigrants. 54 Current treatments like nucleos(t)ide analogs suppress viral replication but rarely achieve functional cure—defined as sustained loss of hepatitis B surface antigen (HBsAg)—leaving patients at lifelong risk of cirrhosis and cancer.

Chronic Hepatitis B: The Silent Liver Threat

Hepatitis B virus (HBV), a DNA virus from the Hepadnaviridae family, primarily targets hepatocytes, the main functional cells of the liver. Acute infection resolves in 90-95% of adults, but 5-10% develop chronic infection, where the virus persists due to immune evasion and T-cell exhaustion. Over decades, this leads to chronic inflammation (hepatitis), fibrosis, cirrhosis, and HCC in 15-40% of cases.

In Canada, reported cases reached 3,524 in 2021 (rate of 9.2 per 100,000), with higher burdens among certain immigrant communities (up to 4% prevalence). 57 Globally, HBV accounts for 38% of liver cancer deaths. Without intervention, the economic toll is immense, including healthcare costs for transplants and lost productivity.

The Woodchuck Model: Nature's Proxy for Human HBV

The eastern woodchuck (Marmota monax) and woodchuck hepatitis virus (WHV) provide the closest natural preclinical model to human HBV. Like HBV, WHV establishes chronic infection, induces hepatitis, and progresses to HCC. Advantages include natural transmission, immune responses akin to humans, and measurable viremia/covalently closed circular DNA (cccDNA)—the viral persistence reservoir absent in rodent models. 93

Limitations? Woodchucks are outbred, larger, and costlier than mice, but their fidelity to HBV oncogenesis makes them invaluable for therapy testing. This UHN study validates the model at single-cell resolution, showing conserved pathological programs. 52

Decoding the Liver: Single-Cell RNA Sequencing Explained

Single-cell RNA sequencing (scRNA-seq) profiles gene expression in individual cells, revealing heterogeneity invisible in bulk analysis. Here, UHN researchers sequenced healthy woodchuck livers (n=8 animals, 52k hepatic cells), chronic WHV livers (n=8, 40k cells), PBMCs, and precision-cut liver slices (PCLS) stimulated ex vivo. Spatial transcriptomics mapped gene activity by liver zonation (periportal to pericentral).

Step-by-step: Tissue dissociation yields single cells/nuclei; barcoding tags transcripts; sequencing reads millions per cell; computational clustering annotates types (hepatocytes, Kupffer cells, T cells, etc.). This atlas captures dynamic shifts in infection. 50

Healthy Liver Architecture: A Baseline for Disease

The atlas depicts woodchuck liver diversity matching human/murine: hepatocytes dominate (zonal gradients), cholangiocytes line bile ducts, stellate/LSECs maintain homeostasis, immune sentinels (Kupffer, T/NK cells) patrol. PBMCs mirror circulating immunity.

Spatial data confirms zonation: glutamine synthesis periportal, lipid metabolism pericentral—blueprints disrupted in disease.

Infection's Cellular Symphony: Immune Exhaustion Unveiled

In chronic WHV, T cells restructure: memory declines, exhausted phenotypes rise (PD1+, TIM3+), echoing human HBV. Dendritic cells (cDC1/cDC2) activate periportally, fueling inflammation. Myeloid cells shift pro-fibrotic; endothelial leakiness promotes fibrosis.

• Exhausted CD8+ T cells: Hallmark, impaired cytotoxicity.
• Dendritic activation: Antigen presentation ramps, but tolerogenic.
• Myeloid expansion: Cytokine storm precursors.

Bridging Species: Conserved Pathways with Human HBV

Crucially, WHV mirrors HBV: Shared gene modules for exhaustion, periportal DC activation, T-cell dysfunction. This cross-species validation strengthens woodchuck utility for cccDNA targeting, immune modulation therapies. 51 For more on the study, see the full paper at Journal of Hepatology.

Toward Functional Cures: Therapeutic Horizons

Atlas identifies targets: Restore T-cell vigor (checkpoint inhibitors), reprogram DCs, halt myeloid fibrosis. Combos with NUCs aim functional cure (HBsAg seroclearance), reducing HCC risk 80-90% post-cure.

Canada's CIHR funds such innovation; UHN's Ajmera Centre pioneers transplants/immunotherapies. Global trials (e.g., siRNA + IFN) leverage models like this. 73

UHN and University of Toronto: Pillars of Canadian Liver Excellence

Affiliated with UofT, UHN's Toronto General Hospital leads transplants (Canada's largest). MacParland's team trains PhDs (e.g., Zoe Clarke), fostering next-gen researchers. This atlas exemplifies collaborative higher ed driving health outcomes.

Explore opportunities at UHN Research Careers.

Combating Liver Cancer: From Atlas to Prevention

HBV-HCC link: 50% cases HBV-attributable. Atlas pinpoints precancerous shifts (e.g., exhausted immunity fosters tumorigenesis). Early surveillance, vaccines (95% effective) key. Canada screens high-risk; atlas accelerates biomarkers.

WHO data: For details, visit WHO Hepatitis B Factsheet. 64

Future Outlook: Accelerating HBV Eradication

Integrate atlas with AI for drug discovery; test CAR-T, gene editors. Canadian leadership via UHN/UofT positions nation forefront. Students: Pursue liver immunology—vital field.

Photo by Mufid Majnun on Unsplash

Why This Matters for Higher Education and Careers

In Canadian universities, such projects train interdisciplinary talent (bioinformatics, immunology). UofT's programs equip grads for biotech. Amid HBV burden, research careers boom—check research positions.